Initial dose intensity has limited impact on the outcome of ABVD chemotherapy for advanced Hodgkin lymphoma (HL): Data from UKLG LY09 (ISRCTN97144519)

W. S. Owadally; M. R. Sydes; J. A. Radford; B. W. Hancock; M. H. Cullen; S. P. Stenning; P. W M Johnson

doi:10.1093/annonc/mdp331

Initial dose intensity has limited impact on the outcome of ABVD chemotherapy for advanced Hodgkin lymphoma (HL): Data from UKLG LY09 (ISRCTN97144519)

W. S. Owadally, M. R. Sydes, J. A. Radford, B. W. Hancock, M. H. Cullen, S. P. Stenning, P. W M Johnson

Research output: Contribution to journal › Article › peer-review

Abstract

Background: This analysis was undertaken to assess the relationship between the dose intensity (DI) of initial chemotherapy and outcome in a large cohort of patients with advanced Hodgkin lymphoma treated in a randomised controlled trial, in which detailed dose data were collected prospectively. Patients and methods: Three-hundred and eighty patients randomly assigned to receive standard doxorubicin, bleomycin, vinblastine and dacarbazine who underwent at least two cycles of treatment were studied. With a median follow-up of 6.9 years, progression-free survival (PFS) from the end of cycle 2 was analysed according to DI during those cycles. Results: During the first two cycles, 25% of patients received >97% of planned DI, 37% received between 86% and 97% and 38% received

Original language	English
Article number	mdp331
Pages (from-to)	568-573
Number of pages	5
Journal	Annals of Oncology
Volume	21
Issue number	3
DOIs	https://doi.org/10.1093/annonc/mdp331
Publication status	Published - 14 Aug 2009

Keywords

ABVD
Chemotherapy
Dose intensity
Hodgkin lymphoma

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1093/annonc/mdp331

Cite this

@article{27f673a3a0fd4c76b1ccc17dc9bca395,

title = "Initial dose intensity has limited impact on the outcome of ABVD chemotherapy for advanced Hodgkin lymphoma (HL): Data from UKLG LY09 (ISRCTN97144519)",

abstract = "Background: This analysis was undertaken to assess the relationship between the dose intensity (DI) of initial chemotherapy and outcome in a large cohort of patients with advanced Hodgkin lymphoma treated in a randomised controlled trial, in which detailed dose data were collected prospectively. Patients and methods: Three-hundred and eighty patients randomly assigned to receive standard doxorubicin, bleomycin, vinblastine and dacarbazine who underwent at least two cycles of treatment were studied. With a median follow-up of 6.9 years, progression-free survival (PFS) from the end of cycle 2 was analysed according to DI during those cycles. Results: During the first two cycles, 25% of patients received >97% of planned DI, 37% received between 86% and 97% and 38% received",

keywords = "ABVD, Chemotherapy, Dose intensity, Hodgkin lymphoma",

author = "Owadally, {W. S.} and Sydes, {M. R.} and Radford, {J. A.} and Hancock, {B. W.} and Cullen, {M. H.} and Stenning, {S. P.} and Johnson, {P. W M}",

note = ", Cancer Research UK, United Kingdom, Medical Research Council, United Kingdom",

year = "2009",

month = aug,

day = "14",

doi = "10.1093/annonc/mdp331",

language = "English",

volume = "21",

pages = "568--573",

journal = "Annals of Oncology",

issn = "1569-8041",

publisher = "Oxford University Press",

number = "3",

}

TY - JOUR

T1 - Initial dose intensity has limited impact on the outcome of ABVD chemotherapy for advanced Hodgkin lymphoma (HL): Data from UKLG LY09 (ISRCTN97144519)

AU - Owadally, W. S.

AU - Sydes, M. R.

AU - Radford, J. A.

AU - Hancock, B. W.

AU - Cullen, M. H.

AU - Stenning, S. P.

AU - Johnson, P. W M

N1 - , Cancer Research UK, United Kingdom, Medical Research Council, United Kingdom

PY - 2009/8/14

Y1 - 2009/8/14

N2 - Background: This analysis was undertaken to assess the relationship between the dose intensity (DI) of initial chemotherapy and outcome in a large cohort of patients with advanced Hodgkin lymphoma treated in a randomised controlled trial, in which detailed dose data were collected prospectively. Patients and methods: Three-hundred and eighty patients randomly assigned to receive standard doxorubicin, bleomycin, vinblastine and dacarbazine who underwent at least two cycles of treatment were studied. With a median follow-up of 6.9 years, progression-free survival (PFS) from the end of cycle 2 was analysed according to DI during those cycles. Results: During the first two cycles, 25% of patients received >97% of planned DI, 37% received between 86% and 97% and 38% received

AB - Background: This analysis was undertaken to assess the relationship between the dose intensity (DI) of initial chemotherapy and outcome in a large cohort of patients with advanced Hodgkin lymphoma treated in a randomised controlled trial, in which detailed dose data were collected prospectively. Patients and methods: Three-hundred and eighty patients randomly assigned to receive standard doxorubicin, bleomycin, vinblastine and dacarbazine who underwent at least two cycles of treatment were studied. With a median follow-up of 6.9 years, progression-free survival (PFS) from the end of cycle 2 was analysed according to DI during those cycles. Results: During the first two cycles, 25% of patients received >97% of planned DI, 37% received between 86% and 97% and 38% received

KW - ABVD

KW - Chemotherapy

KW - Dose intensity

KW - Hodgkin lymphoma

U2 - 10.1093/annonc/mdp331

DO - 10.1093/annonc/mdp331

M3 - Article

C2 - 19684105

SN - 1569-8041

VL - 21

SP - 568

EP - 573

JO - Annals of Oncology

JF - Annals of Oncology

IS - 3

M1 - mdp331

ER -

Initial dose intensity has limited impact on the outcome of ABVD chemotherapy for advanced Hodgkin lymphoma (HL): Data from UKLG LY09 (ISRCTN97144519)

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this